Update: Bloomberg confirms NKP's coverage of the Morgan Stanley-led sale process for Immedica Pharma
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights
December 22, 2023
Impilo has mandated Morgan Stanley to explore ownership options for its specialty pharmaceutical commercialization and distribution platform Immedica Pharma according to multiple sources - Revenues of SEK ~1,000m and EBITDA of SEK ~300m in FY23E (NKP Proprietary)
Update: NBOs were submitted before Christmas in the William Blair-guided sale of privately owned, Austrian-headquartered TT medic, a specialised plastic components manufacturer (CDMO) for the life science industry - opportunity first and exclusively covered by NKP on 12 Dec 2023 (NKP Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights
December 12, 2023
Privately owned TT medic, a specialised plastic components manufacturer (CDMO) for the life science industry, is circled by sponsors and may launch William Blair guided sale early next year off EBITDA of close to EUR 10m - according to multiple sources (NKP Proprietary)
Korona Invest has engaged Translink Corporate Finance to advise on the planned sale of Enmac, a Finnish specialised engineering consulting firm held since 2020, with NBOs due mid-January 2024, acc. to sources - marketed off FY23E sales of EUR ~23m and EBITDA of EUR ~3.6m (NKP Proprietary)
Orifarm, a leading European supplier of parallel-imported and generic pharmaceuticals, is in the early stages of preparing a possible minority stake sale advised by Rothschild, acc. to multiple sources – Revenues of EUR 1,514m (+7% YoY) and EBITDA of EUR 104m in FY22 (NKP Proprietary)
.png){kind=logo}